Research & Development
Genmab receives marketing authorisation in Europe for DARZALEX (Daratumumab) in combination with lenalidomide and dexamethasone in frontline multiple myeloma
20 November 2019 - Genmab A/S (CPH:GMAB), a biotechnology company specialising in the creation and development of differentiated antibody therapeutics for the treatment of cancer, announced on Tuesday...
Orphazyme announces receipt of Breakthrough Therapy Designation from US FDA for arimoclomol to treat Niemann-Pick Disease Type C
20 November 2019 - Biopharmaceutical company Orphazyme A/S (CPH:ORPHA.CO) announced on Tuesday the grant by the US Food and Drug Administration (FDA) of Breakthrough Therapy Designation for arimoclomo...
Consistent Effects of Farxiga in Heart Failure Patients with Reduced Ejection Fraction Shown in New Analyses from Landmark Phase III DAPA-HF Trial
19 November 2019 - - British-Swedish pharmaceutical company AstraZeneca (OTC: AZNCF) released new data from five additional analyses of the landmark Phase III DAPA-HF trial, which showed that Farxiga ...
Aveo Presents Updated OS and Subgroup Data from Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma
19 November 2019 - - US-based biopharmaceutical company Aveo Oncology (NASDAQ: AVEO) has presented updated data from the Phase 3 TIVO-3 trial.
The data were presented on Saturday, November 16, ...
US FDA Approves Pfizer's Biosimilar, Abrilada for Multiple Inflammatory Conditions
19 November 2019 - - The United States Food and Drug Administration has approved US-based pharmaceutical company Pfizer Inc.'s (NYSE: PFE) Abrilada (adalimumab-afzb), as a biosimilar to Humira&nb...
BioPorto to provide additional patient information to US FDA for regulatory clearance of The NGAL Test for paediatric risk assessment of AKI
19 November 2019 - BioPorto A/S (CPH:BIOPOR), an in vitro diagnostics company, reported on Monday that it will provide additional patient information in support of its US application for regulatory cl...
Related Headlines

US FDA grants approval to Novartis' Adakveo

US FDA approves first contact lens indicated to slow the progression of myopia in children

The FDA authorises marketing of duodenoscopes with disposable elevator component for use with endoscopic devices

Novartis wins FDA approval of Adakveo to reduce frequency of pain crises in sickle cell disease patients

Cantargia's pre-IND meeting with US FDA results in advancement of development of antibody CAN04

US FDA grants approval to Shionogi's Fetroja

US FDA grants AstraZeneca and Merck New Drug Application and priority review for Selumetinib

US FDA Accepts Regulatory Submission of New Drug Application for Selumetinib in Neurofibromatosis Type 1 and Grants Priority Review

Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComa

AstraZeneca and MSD announce FDA acceptance of NDA for selumetinib in neurofibromatosis type 1 and Priority Review

Ultromics gains FDA clearance for AI-powered EchoGo to help in the earlier detection of cardiovascular disease

FDA approves Brukinsa therapy to treat patients with relapsed and refractory mantle cell lymphoma

FDA approves new antibacterial drug Fetroja to treat complicated urinary tract infections

Newly Published Research Demonstrates Ability of Hologic's Assay to Detect Mycoplasma Genitalium, "the Silent Epidemic"

Merck's ERVEBO Ebola Zaire Vaccine Granted Conditional Approval in the European Union